Company overview
MaxCyte provides flow electroporation systems like ExPERT instruments for high-efficiency transfection of diverse cell types, from primary cells to billions in scale, supporting cell therapy, gene editing, protein production, and vaccine development. Their GMP-compatible platforms enable seamless scalability without re-optimization, ideal for R&D to manufacturing transitions in pharma and biotech. Applications include CRISPR engineering, CAR-mRNA expression, virus-like particles, and cell-based assays.
MaxCyte is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include electroporation systems, cell therapy transfection, gene editing platform, gmp electroporation, flow electroporation.
Structured facts
- Website
- https://maxcyte.com
- Markets served
- United States & Americas
- Keywords
- electroporation systems, cell therapy transfection, gene editing platform, gmp electroporation, flow electroporation
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What cell types and scales can MaxCyte electroporation handle?
- MaxCyte systems transfect from 75,000 to 20 billion cells, including primary cells, immortalized lines, T cells, macrophages, HEK293T, and stem cells, with high efficiency and viability across small-scale R&D to GMP manufacturing.
- Is MaxCyte's technology GMP-compatible for clinical applications?
- Yes, platforms like ExPERT GTx are GMP-compatible, used for manufacturing virus-like particles with CRISPR-Cas9 RNPs and supporting cell therapy from discovery to Phase I.
- What therapeutic applications does MaxCyte support?
- MaxCyte enables cell therapy, gene editing (CRISPR), CAR-mRNA in Tregs, antibody/protein production, viral vectors, vaccines, and cell-based assays with scalable transient transfection.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
